(Q73509362)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

David L Garver

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Rebecca L Tamas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Jennifer A Holcomb

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

11 June 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

1515-1520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12799618%20AND%20SRC:MED&resulttype=core&format=json

Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Cytokine profiles in drug-naive schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Physiological and pathological roles of interleukin-6 in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Regulation of an oligodendrocyte progenitor cell line by the interleukin-6 family of cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Effect of risperidone on serum cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

A separate disease within the syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Plasma cytokine response to surgical stress in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

The immune system and schizophrenia. An integrative view.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Progression of cerebroventricular enlargement and the subtyping of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Elevated circulating levels of IL-6 in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Search for schizophrenia susceptibility genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Borna disease virus in brains of North American and European people with schizophrenia and bipolar disorder. Bornavirus Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Expression of interleukin (IL)-1 beta, IL-6 and their respective receptors in the normal rat brain and after injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021

Endogenous retroviruses and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300217

7 January 2021